Thu, 18 June 2015
The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on their tumor. Should we be using this as a biomarker?
Direct download: GRACEcast-333_ASCO_2015_Immunotherapy_NSCLC_Biomarker_Selection.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT